Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Okano, Tomohito, Kobayashi, Tetsu, Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Toda, Masaaki, Fujimoto, Hajime, Nakahara, Hiroki, Okano, Yuko, Takeshita, Atsuro, Nishihama, Kota, Saiki, Haruko, Tomaru, Atsushi, Fridman D’Alessandro, Valeria, Ishida, Satoru, Sugimoto, Hiromi, Takei, Yoshiyuki, Gabazza, Esteban C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774321/
https://www.ncbi.nlm.nih.gov/pubmed/33390975
http://dx.doi.org/10.3389/fphar.2020.593620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774321/
https://www.ncbi.nlm.nih.gov/pubmed/33390975
http://dx.doi.org/10.3389/fphar.2020.593620

Ejemplares similares